Search
Clinician Ordering Portal
Practice Integration
Easily integrate TissueCypher into your practice
TissueCypher fits seamlessly into the management of patients with Barrett’s esophagus. The test can be run on existing esophageal pinch biopsies and is ordered after a pathologic diagnosis of non-dysplastic, indefinite, or low-grade Barrett’s esophagus. Once the test is ordered by the treating clinician, Castle's clinical staff works with your pathology lab to acquire the tissue samples and process them at the Castle lab, delivering reports within 18-20 business days.
TissueCypher-guided patient management
More than 3,000 clinicians across the U.S. have ordered TissueCypher. In our Cases with Castle series, watch physicians discuss how TissueCypher guided management for real-world patients.
What’s included in the report?
-
The risk classification groups patients based on their risk of progression.
-
The risk score is based on a scale from 0-10. The lower the number, the lower the risk of progression.
-
A 5-year probability of progression is associated with the patient’s risk score.
Translating risk into action
TissueCypher risk classifications can be used together with traditional dysplasia-based grading to give a more personalized risk assessment. This is especially important for the vast majority of patients receiving a diagnosis of non-dysplastic Barrett’s esophagus:
- Non-dysplastic BE + TissueCypher low risk means those patients collectively have a 5-year risk of progression of 1.45%, providing confidence to follow guideline-based recommendations for 3-5 year surveillance. *
- Non-dysplastic BE + TissueCypher high risk means those patients collectively have a 5-year risk of progression of 16%, which is nearly twice the level of risk for patients with expert-confirmed low-grade dysplasia. Escalated care plans may be appropriate given their elevated individual risk
Supplementing the current treatment paradigm
TissueCypher results can be used in conjunction with histology to help recommend long-interval surveillance for patients with low risk of progression. For patients with elevated risk of progression, TissueCypher supports the use of short-interval surveillance or Endoscopic Eradication Therapy (EET).
Using TissueCypher to guide personalized care for Barrett’s esophagus
Dr. John Lipham discusses how his team has developed a tailored clinical algorithm based on TissueCypher results to guide the management of patients with Barrett’s esophagus.
